Hayden E. Klein

The FDA approved telisotuzumab vedotin-tllv (Emrelis; AbbVie) to treat adults with locally advanced or metastatic, non-squamous non–small cell lung cancer (NSCLC) with high c-Met protein overexpression who have received a prior systemic treatment.1 Also referred to as Teliso-V, telisotuzumab vedotin is […]

Three common maternal cardiometabolic risk factors arising during pregnancy were associated with increased systolic and diastolic blood pressure in offspring, according to a study published in JAMA Network Open.1 Researchers specifically looked at cases of prepregnancy obesity, gestational diabetes, and

Patients with metabolic dysfunction–associated steatohepatitis (MASH) saw reductions in liver fibrosis and steatohepatitis after 72 weeks of treatment with semaglutide (Ozempic, Wegovy; Novo Nordisk) in a new study published in The New England Journal of Medicine.1 This is the first

The Rockwood Frailty Index (FI) has been shown to significantly enhance prediction of cardiovascular disease (CVD) risk beyond traditional methods like the Framingham Risk Score (FRS) and the Systematic Coronary Risk Evaluation (SCORE2)/SCORE2-Older Persons (OP) in middle-aged and older adults

Zanubrutinib demonstrated a more favorable safety profile than ibrutinib for patients with chronic lymphocytic leukemia (CLL), with fewer serious adverse events (SAEs) and lower rates of treatment discontinuation due to toxicity, according to a study published in Hematological Oncology.1 Specifically,

The FDA recently approved mirdametinib (Gomekli; SpringWorks Therapeutics) to treat adults and children aged 2 and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not seeking complete surgical resection.1 This approval was based on findings from

With rising oncology treatment costs and potentially billions of dollars anticipated in health care cuts, providers must optimize infusion pharmacy services to navigate reimbursement challenges, says Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC, assistant vice president of system oncology pharmacy

As artificial intelligence (AI) continues to integrate into dermatology, it’s important to not only ask how doctors are using it, but also how patients perceive it. One popular way AI is being used in dermatology is through skin cancer screening.

In an interview with The American Journal of Managed Care® (AJMC®), Douglas Flora, MD, FACCC, executive medical director of oncology services at St. Elizabeth Healthcare, and editor in chief of AI in Precision Oncology, discussed how artificial intelligence (AI) can expedite

Five years after the initial wave of COVID-19, its long-term effects continue to impact patient recovery, particularly for those with severe infections, cancer histories, or limited health care access. While COVID-19 is no longer an active public health emergency, it